

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

**Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): **March 17, 2015**

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of
Incorporation)

000-30319

(Commission File Number)

94-3265960

(I.R.S. Employer Identification Number)

**951 Gateway Boulevard
South San Francisco, California 94080
(650) 238-9600**

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On March 17, 2015, the U.S. Food and Drug Administration (the "FDA") posted on its web site the FDA Briefing Information (the "FDA Briefing Information") for the March 19, 2015 meeting of the Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (the "Advisory Committee Meeting") to review the supplemental New Drug Application sponsored by GlaxoSmithKline ("GSK") for BREO® ELLIPTA® (fluticasone furoate/vilanterol) as a once-daily inhaled treatment for asthma in patients aged 12 years and older. In addition to the FDA Briefing Information, the FDA also posted GSK's Briefing Information (the "GSK Briefing Information") for the Advisory Committee Meeting on its web site. The FDA Briefing Information and the GSK Briefing Information posted by the FDA may be obtained by following this pathway to the FDA web site: <http://www.fda.gov/AdvisoryCommittees/Calendar/ucm433812.htm>.

The information in this report is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report.

* * *

By filing this report and furnishing this information, Theravance, Inc. (the "Company") makes no admission as to the materiality of any information in this report. The information contained in this report is intended to be considered in the context of the Company's filings with the SEC and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update

or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERAVANCE, INC.

Date: March 17, 2015

By: /s/ Eric d'Esparbes
Eric d'Esparbes
Chief Financial Officer